BerGenBio Announces Final Bemcentinib Phase 2 Data in AML and MDS Presented at the 2023 ASH Meeting

  • Bemcentinib is an oral highly selective AXL inhibitor in development for cancer and severe respiratory infections
  • Final Phase 2 data indicates a favorable safety profile with promising efficacy in AML and MDS patients


BERGEN, Norway, December 11, 2023, – BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, today announced that a poster highlighting final results from a Phase 2 clinical study of its highly selective AXL inhibitor bemcentinib in patients with Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) was presented during the 2023 American Society of Hematology (ASH) Annual Meeting being on December 9th in San Diego, CA.


The data presented by Professor Sonja Loges, MD, Ph.D. of the University Medical Centre Mannheim, Heidelberg, Germany, showed that bemcentinib was well tolerated in AML and MDS patients. Durable responses were observed across all cohorts with bemcentinib as monotherapy and in combination with chemotherapy. In addition, longitudinal samples analyzed from patients enrolled in the study showed that bemcentinib inhibited pAXL and downstream markers of activation.

Martin Olin, Chief Executive Officer of BerGenBio commented “This large Phase 2 study included 122 patients in several cohorts of AML and MDS patients treated with bemcentinib monotherapy or in combination with two different chemotherapies.  We are particularly encouraged by the monotherapy activity of bemcentinib in this study which adds to the mounting evidence of the role of bemcentinib in restoring the function of patients' immune response to cancer.”





Martin Olin CEO, BerGenBio ASA


Rune Skeie, CFO, BerGenBio ASA


Investor Relations / Media Relations


Jan Lilleby




About Bemcentinib


Bemcentinib is a potentially first-in-class, potent and highly selective inhibitor of the tyrosine kinase AXL.  Extensive studies confirm the ability to combine bemcentinib with immune checkpoint inhibitors, chemotherapies and targeted therapies with the goal of improving a patient’s immune response and delaying the development of chemoresistance.  Bemcentinib is currently being investigated in combination with immune checkpoint inhibition and chemotherapy in first line NSCLC patients harboring mutations in the STK11 gene, a known prognostic factor of poor response to existing therapies.


About BerGenBio ASA


BerGenBio is a clinical-stage biopharmaceutical company focused on developing transformative drugs targeting AXL as a potential cornerstone of therapy for aggressive diseases, including cancer and severe respiratory infections. The Company is focused on its proprietary lead candidate, bemcentinib, a potentially first-in-class selective AXL inhibitor in development for STK11 mutated NSCLC and COVID-19.


BerGenBio is based in Bergen, Norway with a subsidiary in Oxford, UK. The company is listed on the Oslo Stock Exchange (ticker: BGBIO). For more information, visit


Forward looking statements


This announcement may contain forward-looking statements, which as such are not historical facts, but are based upon various assumptions, many of which are based, in turn, upon further assumptions. These assumptions are inherently subject to significant known and unknown risks, uncertainties, and other important factors. Such risks, uncertainties, contingencies and other important factors could cause actual events to differ materially from the expectations expressed or implied in this announcement by such forward-looking statements.


This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.